Shocking! Can’t the rich countries postpone vaccination of their less susceptible population & donate excess quota of vaccines to the underprivileged, LMICs of Africa?
Need such policies to spare more vaccine doses for the needy. We now have plenty of data on the futility of the 2nd vaccine dose to the pre-infected, seropositive individuals
This research has relevance to India also.
A single dose #ChAdOx1 nCoV-19 vaccine serves as an effective immune booster after priming with natural #SARSCoV2 infection up to at least 11 months post infection.
We are getting more data on #AZ/#Covishield vaccine also. A small study from #Agra concludes adequacy of a single dose in previously infected. Further, pre-infected subjects also had significantly low reinfection rates than uninfected with/ 2 doses of AZ
We know that the two Ad-vector based vaccines, #AstraZeneca & #JNJ lead to clot-related complications like cerebral venous sinus thrombosis. We also know these events are referred to as ‘Vaccine induced Thrombotic Thrombocytopenia’ (VITT). But what lead to these complications? 1/
Now a new explanation for VITT seen with vector vaccines. “Vaccine-Induced #Covid19 Mimicry” Syndrome: Splice reactions within the #SARSCoV2 Spike ORF result in ‘Spike protein variants’ that may cause thromboembolic events in patients immunized with vector-based vaccines 2/
These soluble Spike #variants may initiate severe side effects when binding to #ACE2-expressing #endothelial cells in blood vessels 3/
Now, it seems, we are close to solve this puzzle. A spurt of studies are favoring natural infection. In this new study from Lombardy, Italy, only 0.3% people got re-infected 1 Year after primary infection. Uninfected had 13-15 times higher infections 1/ jamanetwork.com/journals/jamai…
Another study documenting at least 1 year protection following natural infection: medrxiv.org/content/10.110… 2/
Earlier we thought natural SARSCoV2 infection fails to produce long lasting plasma cells in the bone marrow. But now we have evidence 👇
Even mild #Covid infection induces a robust antigen-specific, long-lived plasma cells in 3/ nature.com/articles/s4158…
Which arm is crucial for viral clearance & protection against #SARSCoV2? 1/
Early on in the #pandemic questions arose regarding how #SARSCoV2 is cleared during acute/primary infection & what aspects of the #adaptive immune were necessary and sufficient for protection from repeat infection 2/
Using mouse models of SARSCoV2,@BenIsraelow Rt al demonstrate that both humoral and cellular adaptive immunity contributes to viral clearance in the setting of primary infection 3/
How the #Covid pandemic ends: The truth of the matter is that pandemics always end. And to date #vaccines have never played a significant role in ending them........ 1/statnews.com/2021/05/19/how…
......that doesn’t mean #vaccines aren’t playing a critical role this time. Far fewer people will die from #Covid19 because of them 2/
Experience from the last 4 pandemics would suggest that viruses morph from pandemic pathogens to endemic sources of disease within a year & a half or two of emerging. But all of those pandemics were flu pandemics. A different pathogen could mean we’ll see a different pattern 3/
#Mixing vaccines: Study from #Spain indicates it is likely safe to have taken #AstraZeneca then switch to the #BNT1622b vaccine for 2nd dose—found to be “highly immunogenic & safe.” Neutralization with Pfizer for 2nd dose increased 7 folds 1/
Presence of IgG Abs was between 30 to 40 times higher in people who got the follow-up #BNT1622b shot than in a control group who only received one #AstraZeneca dose 2/
Meanwhile, the presence of #Neutralising Abs arose 7 folds after a #Pfizer dose, significantly more than the doubling effect observed after a 2nd AZ shot 3/
The #Indian variant (#B16172) may be the most transmissible variant yet identified!!
This variant is 60% more transmissible than the #UK variant (#B117), & 2.6 times more transmissible than the original strain (B1)!
The #B16172 has now become the dominant variant in almost all key states on India. Data patchy (n=4480 since Jan. 2021 of which 1690 B.1.617+) but clear patterns. Data courtesy @TWenseleers
According to a new modelling study shared by @TWenseleers, the Indian VOC #B16172 would have a growth rate advantage of 7% per day over B.1.617.1 or of 10% per day relative to the UK variant B.1.1.7.